This week
3
new MHRA Innovation Passports, in Huntington’s disease, lung cancer and early Alzheimer’s disease.
Source: MHRA (9 Nov 2026)
ILAP is the UK’s Innovative Licensing and Access Pathway. A passport brings coordinated support from the MHRA, NICE, the SMC, AWTTC and NHS partners while a medicine is still in development. The next application round is open until 11 February 2027.
Why it matters
The strongest launches invest earlier.
Launch research keeps landing on the same finding: the most successful launches invest earlier and more thoughtfully in pre-launch medical and commercial work. ILAP is a structured way to start that conversation with the system, within the rules.
For launch teams
Listen early. Plan together.Launch ready.
01
Start together
Bring market access and medical in at the start, not just regulatory.
02
Plan from what you hear
Use what the system tells you to shape evidence plans and engagement plans, keeping pre-licence activity within the ABPI Code.
03
Feed it back
Share UK insight with global, so launch sequencing reflects how the NHS actually adopts.